☆ 4.6 Article

Androgen receptor expression on circulating tumor cells in metastatic breast cancer

PLOS ONE (2017)

期刊

PLOS ONE

卷 12, 期 9, 页码 -

出版社

PUBLIC LIBRARY SCIENCE

DOI: 10.1371/journal.pone.0185231

关键词

类别

Multidisciplinary Sciences

资金

Morgan Welch Inflammatory Breast Cancer Research Program
State of Texas Rare and Aggressive Breast Cancer Research Program
MD Anderson Cancer Center's Cancer Center Support Grant from the National Cancer Institute [CA016672]
Epic Sciences

向作者/读者索取更多资源

Protocol

社区支持

Reagent

社区支持

摘要

Purpose Androgen receptor (AR) is frequently detected in breast cancers, and AR-targeted therapies are showing activity in AR-positive (AR+) breast cancer. However, the role of AR in breast cancers is still not fully elucidated and the biology of AR in breast cancer remains incompletely understood. Circulating tumor cells (CTCs) can serve as prognostic and diagnostic tools, prompting us to measure AR protein expression and conduct genomic analyses on CTCs in patients with metastatic breast cancer. Methods Blood samples from patients with metastatic breast cancer were deposited on glass slides, subjected to nuclear staining with DAPI, and reacted with fluorescent-labeled antibodies to detect CD45, cytokeratin (CK), and biomarkers of interest (AR, estrogen receptor [ER], and HER2) on all nucleated cells. The stained slides were scanned and enumerated by non-enrichment- based non-biased approach independent of cell surface epithelial cell adhesion molecule (EpCAM) using the Epic Sciences CTC platform. Data were analyzed using established digital pathology algorithms. Results Of 68 patients, 51 (75%) had at least 1 CTC, and 49 of these 51 (96%) had hormone-receptor- positive (HR+)/HER2-negative primary tumors. AR was expressed in CK+ CTCs in 10 patients. Of these 10 patients, 3 also had ER expression in CK+ CTCs. Single cell genomic analysis of 78 CTCs from 1 of these 3 patients identified three distinct copy number patterns. AR+ cells had a lower frequency of chromosomal changes than ER+ and HER2+ cells. Conclusions CTC enumeration and analysis using no enrichment or selection provides a non-biased approach to detect AR expression and chromosomal aberrations in CTCs in patients with metastatic breast cancer. The heterogeneity of intrapatient AR expression in CTCs leads to the new hypothesis that patients with AR+ CTCs have heterogeneous disease with multiple drivers. Further studies are warranted to investigate the clinical applicability of AR+ CTCs and their heterogeneity.

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

主要评分

4.6

评分不足

次要评分

新颖性

重要性

科学严谨性

评价这篇论文

Transcriptome Profiling of Circulating Tumor Cells to Predict Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer

Levi Groen, Iris Kloots, David Englert, Kelly Seto, Lana Estafanos, Paul Smith, Gerald W. Verhaegh, Niven Mehra, Jack A. Schalken

Summary: The clinical utility of circulating tumor cells (CTC) as a non-invasive multipurpose biomarker is well recognized. The earliest methods for enriching CTCs relied on antibody-based positive selection, but it has limitations in capturing the heterogeneity of cancer. This study used the recently FDA-approved Parsortix (R) technology to enrich CTCs from prostate cancer patients and found that targeted CTC transcriptome profiling may be predictive of therapy response.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)